| # | Name | Description | Category | Type | Source | Website |
|---|
| # | Opportunity | Type | Region / Country | Amount | Deadline | Source |
|---|---|---|---|---|---|---|
| 35501 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Mesalazin, ATC A07EC02 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35502 | Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Bosutinib, ATC L01EA04 (OBG) für die Zeit 01.10.2024 - 30.09.2026 Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35503 | Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Dapagliflozin, ATC A10BK01 (OBO) für die Zeit 01.10.2024 - 30.09.2026 Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35504 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lacosamid (ausgenommen Darreichungsform Filmtabletten), ATC N03AX18 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35505 | Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Allergenextrakt aus Wiesenlieschgras, Ruchgras, etc. (ausschl. SUT), ATC V01AA02 f. d. Z. 01.10.24-30.09.26 Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35506 | Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Faricimab, ATC S01LA09 (OBO) für die Zeit 01.10.2024 - 30.09.2026 Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35507 | Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Allergenextrakt aus ausschl. Wiesenlieschgraspollen (ausschl. SUT), ATC V01AA02 f. d. Z. 01.10.24-30.09.26 Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35508 | Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Bimekizumab, ATC L04AC21 (OBO) für die Zeit 01.10.2024 - 30.09.2026 Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35509 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Raltegravir, ATC J05AJ01 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35510 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lisdexamfetamin, ATC N06BA12 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35511 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pomalidomid, ATC L04AX06 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35512 | Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Dapagliflozin + Metformin, ATC A10BD15 (OBO) für die Zeit 01.10.2024 - 30.09.2026 Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35513 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Treprostinil, ATC B01AC21 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35514 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Miglustat, ATC A16AX06 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35515 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Latanoprost, ATC S01ED61 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35516 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Telmisartan, ATC C09CA07 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35517 | Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Febuxostat, ATC M04AA03 Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35518 | Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2024-08 Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadli... | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35519 | Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35520 | Germany – Pharmaceutical products – OpenHouse-Verfahren Diverse Arzneimittelwirkstoffe ab 01.10.2024 Buyer: AOK Rheinland/Hamburg - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline:... | Tender Procurement Contract | Germany | Not provided on the source page. Please check the official source. | Open Aug 5, 2026 Open | TED / Tenders Electronic Daily |
|
Source description
Buyer: AOK Rheinland/Hamburg - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05 |
||||||
| 35521 | Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Trainin... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Aug 6, 2026 Open | Grants.gov |
|
Source description
This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and career development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of [trainees] as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. |
||||||
| 35522 | Fiscal Year 2024 Flood Mitigation Assistance The Flood Mitigation Assistance (FMA) grant program makes federal funds available to states, U.S. territories, federally recognize... | Grant Cash Grant | United States | Award range: $0 - $0 | Open Aug 6, 2026 Open | Grants.gov |
|
Source description
The Flood Mitigation Assistance (FMA) grant program makes federal funds available to states, U.S. territories, federally recognized tribal governments, and local governments to reduce or eliminate the risk of repetitive flood damage to buildings and structures insured under the National Flood Insurance Program (NFIP) in participating communities. FMA funds a variety of flood mitigation activities that are designed to reduce flood risk to policyholders in an effort to reduce the NFIP’s financial exposure.Applicants can submit applications for this funding opportunity through FEMA Grants Outcomes (GO). Access the system at https://go.fema.gov/ |
||||||
| 35523 | DoW Peer Reviewed Medical, Technology/Therapeutic Development Award Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, a pr... | Grant Mixed | United States | Not provided on the source page. Please check the official source. | Open Aug 6, 2026 Open | Grants.gov |
|
Source description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, a product-driven award mechanism, intends to support the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. Products in development should address or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families.Distinctive Features: For the PRMRP Technology/Therapeutic Development Award, the program expects the research proposed will take an already established proof-of-concept or prototype through the final stages of preclinical development. The PRMRP also expects that the research outcome will be a regulatory filing or translation of findings into clinical practice, as applicable.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $67.2M to fund approximately 12 Technology/Therapeutic Development Award applications with total cost caps of $5.6M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awar... |
||||||
| 35524 | DoW Peer Reviewed Medical, Lifestyle and Applied Health Research Award Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Lifestyle and Applied Health Research Award su... | Grant Mixed | United States | Not provided on the source page. Please check the official source. | Open Aug 6, 2026 Open | Grants.gov |
|
Source description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Lifestyle and Applied Health Research Award supports clinical research and/or clinical trials using a combination of scientific disciplines including occupational science, psychology, psychometrics, biostatistics and epidemiology, surveillance, implementation science, and population health. Applications must address and provide a solution to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.Distinctive Features: This funding opportunity requires patient advocate participation. The patient advocate will be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas. Animal research is not allowed.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $16.8M to fund approximately four Lifestyle and Applied Health Research Award applications with total cost caps of $4.2M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. |
||||||
| 35525 | DoW Tuberous Sclerosis Complex, Clinical Translational Research Award Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CT... | Grant Cash Grant | United States | Not provided on the source page. Please check the official source. | Open Aug 6, 2026 Open | Grants.gov |
|
Source description
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. |
||||||